JQ1 may exert its antiproliferative effect by suppressing BRD2 in solid tumors, including NSCLC, where, though, its clinical utilization is severely limited by a different sensitivity among cancer cell subtypes [28, 44, 45, 46]. Here, BRD2 is linked to cancer.